Biogen (BIIB)
(Delayed Data from NSDQ)
$221.42 USD
+3.91 (1.80%)
Updated May 6, 2024 04:00 PM ET
After-Market: $221.41 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 81 - 100 ( 793 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
BIIB080 Might be Next for an Accelerated Approval; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q23 First Take: About As Expected -- Starting To See Pipeline Prioritization
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Getting Fit Doesn''t Happen Overnight -- Thoughts on 1Q23 Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Commercial Biotech Preview: Let''s Get It Started
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 4/7/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/31/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/17/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Win for Surrogate Biomarkers in CNS diseases-Broader Implications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/10/23
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/3/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L